Filing Details
- Accession Number:
- 0001012975-17-000069
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2017-01-31 16:16:40
- Reporting Period:
- 2017-01-31
- Filing Date:
- 2017-01-31
- Accepted Time:
- 2017-01-31 16:16:40
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1370053 | Anaptysbio Inc | ANAB | () | 4 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1018534 | D Alan Frazier | 601 Union Street, Suite 3200 Seattle WA 98101 | No | No | Yes | No | |
1341169 | Frazier Healthcare V, Lp | 601 Union Street, Suite 3200 Seattle WA 98101 | No | No | Yes | No | |
1344203 | J Nader Naini | 601 Union Street, Suite 3200 Seattle WA 98101 | No | No | Yes | No | |
1346944 | Fhm V, Llc | 601 Union Street, Suite 3200 Seattle WA 98101 | No | No | Yes | No | |
1346948 | Fhm V, Lp | 601 Union Street, Suite 3200 Seattle WA 98101 | No | No | Yes | No | |
1365617 | J Patrick Heron | 601 Union Street, Suite 3200 Seattle WA 98101 | No | No | Yes | No | |
1531105 | R Nathan Every | 601 Union Street, Suite 3200 Seattle WA 98101 | No | No | Yes | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2017-01-31 | 1,428,571 | $0.00 | 1,428,571 | No | 4 | C | Direct | |
Common Stock | Acquisiton | 2017-01-31 | 604,055 | $0.00 | 604,055 | No | 4 | C | Direct | |
Common Stock | Acquisiton | 2017-01-31 | 195,751 | $0.00 | 195,751 | No | 4 | C | Direct | |
Common Stock | Acquisiton | 2017-01-31 | 733,740 | $0.00 | 733,740 | No | 4 | C | Indirect | See footnote |
Common Stock | Acquisiton | 2017-01-31 | 209,095 | $0.00 | 209,095 | No | 4 | C | Indirect | See footnote |
Common Stock | Acquisiton | 2017-01-31 | 311,291 | $15.00 | 311,291 | No | 4 | P | Indirect | See footnote |
Common Stock | Acquisiton | 2017-01-31 | 88,709 | $15.00 | 88,709 | No | 4 | P | Indirect | See footnote |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | C | Direct | |
No | 4 | C | Direct | |
No | 4 | C | Direct | |
No | 4 | C | Indirect | See footnote |
No | 4 | C | Indirect | See footnote |
No | 4 | P | Indirect | See footnote |
No | 4 | P | Indirect | See footnote |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Series B Preferred Stock | Disposition | 2017-01-31 | 1,428,571 | $0.00 | 1,428,571 | $0.00 |
Common Stock | Series C Preferred Stock | Disposition | 2017-01-31 | 604,055 | $0.00 | 604,055 | $0.00 |
Common Stock | Series C-1 Preferred Stock | Disposition | 2017-01-31 | 195,751 | $0.00 | 195,751 | $0.00 |
Common Stock | Series D Preferred Stock | Disposition | 2017-01-31 | 733,740 | $0.00 | 733,740 | $0.00 |
Common Stock | Series D Preferred Stock | Disposition | 2017-01-31 | 209,095 | $0.00 | 209,095 | $0.00 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
0 | No | 4 | C | Direct | ||
0 | No | 4 | C | Direct | ||
0 | No | 4 | C | Direct | ||
0 | No | 4 | C | Indirect | ||
0 | No | 4 | C | Indirect |
Footnotes
- The Series B Preferred Stock converted into Common Stock on a 1-to-1 basis immediately prior to the consummation of the Issuer's initial public offering without payment of considerations. The Series B Preferred stock were convertible automatically immediately prior to the consummation of the Issuer's initial public offering, and the shares had no expiration date.
- The Series C Preferred Stock converted into Common Stock on a 1-to-1 basis immediately prior to the consummation of the Issuer's initial public offering without payment of considerations. The Series C Preferred stock were convertible automatically immediately prior to the consummation of the Issuer's initial public offering, and the shares had no expiration date.
- The Series C-1 Preferred Stock converted into Common Stock on a 1-to-1 basis immediately prior to the consummation of the Issuer's initial public offering without payment of considerations. The Series C-1 Preferred stock were convertible automatically immediately prior to the consummation of the Issuer's initial public offering, and the shares had no expiration date.
- The Series D Preferred Stock converted into Common Stock on a 1-to-1 basis immediately prior to the consummation of the Issuer's initial public offering without payment of considerations. The Series D Preferred stock were convertible automatically immediately prior to the consummation of the Issuer's initial public offering, and the shares had no expiration date.
- Represents shares held by Frazier Healthcare V, L.P., an affiliate of Frazier Healthcare Partners. Each of the Reporting Persons disclaims beneficial ownership of the shares except to the extent of their pecuniary interest therein, if any.
- Represents shares held by Frazier Healthcare VII, L.P., an affiliate of Frazier Healthcare Partners. Each of the Reporting Persons disclaims beneficial ownership of the shares except to the extent of their pecuniary interest therein, if any.
- Represents shares held by Frazier Healthcare VII-A, L.P., an affiliate of Frazier Healthcare Partners. Each of the Reporting Persons disclaims beneficial ownership of the shares except to the extent of their pecuniary interest therein, if any.